Many drugs that target amyloid-β (Aβ) in Alzheimer disease (AD) have failed to demonstrate
clinical efficacy. However, four anti-Aβ antibodies have been shown to mediate the removal …

Biomarkers for neurodegenerative diseases are needed to improve the diagnostic workup in
the clinic but also to facilitate the development and monitoring of effective disease-modifying …

Alzheimer's disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals …

Importance There is currently no consensus as to which biomarkers best predict longitudinal
tau accumulation at different clinical stages of Alzheimer disease (AD). Objective To …

Staging the severity of Alzheimer's disease pathology using biomarkers is useful for
therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face …

The chronological progression of brain atrophy over decades, from pre-symptomatic to
dementia stages, has never been formally depicted in Alzheimer's disease. This is mainly …

Alzheimer's disease (AD) is reported to be closely linked with abnormal lipid metabolism. To
gain a more comprehensive understanding of what causes AD and its subsequent …

A key hallmark of Alzheimer's disease (AD) pathology is the intracellular accumulation of tau
protein in the form of neurofibrillary tangles across large-scale networks of the human brain …

The apolipoprotein E (APOE) ε4 allele is strongly linked with cerebral β-amyloidosis, but its
relationship with tauopathy is less established. We investigated the relationship between …

Posterior cortical hypometabolism measured with 18F-fluorodeoxyglucose (FDG)-PET is a
well-known marker of Alzheimer's disease-related neurodegeneration, but its associations …